Krsnaa Diagnost. Q3 FY26 Earnings Analysis

- Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. 600-1,000 crores sales from retail alone. - Revenue growth expected in higher teens percentage over next couple of years. - Q4 FY '26 expected to reach Rs. 100 crore quarterly run rate in retail business due to fast expansion. - Volume growth strategies include introducing wellness packages and advanced test menus, supporting sustainable growth in both PPP and retail channels. - Rajasthan PPP contract expected to kick in FY '27 onwards, providing significant revenue uptick. - Overall revenue expected to grow robustly with retail contributing 8-10% in FY '26, accelerating to 15-20% in next financial year. - Despite temporary receivable-related challenges, growth momentum in both B2G and B2B segments continues. - Anticipated operating leverage and margin improvement as retail volumes scale up.

- Krsnaa Diagnostics expects robust earnings growth, with EBITDA up 18% YoY to Rs. 60 crore and PAT increasing 22% YoY to Rs. 24 crore in Q2 FY '26. - EPS for Q2 FY '26 improved by 24% YoY to Rs. 7.25. - Retail segment, growing rapidly, is anticipated to contribute 8%-10% of revenue in FY '26, accelerating to 15%-20% in FY '27, enhancing margins and profitability. - The company targets retail revenue to reach 40%-50% in five years, driving overall revenue scale-up. - Operational efficiency and margin expansion are ongoing priorities, supported by technology and cost leadership. - Break-even for retail segment is expected around Rs. 100 crore revenue run rate by Q4 FY '26, further boosting profitability. - Overall revenue growth outlook is in the "higher teens" percentage range in the near term.

- For the current fiscal year, excluding Rajasthan, Krsnaa Diagnostics has planned CAPEX of Rs. 150 crores to Rs. 170 crores. - Rs. 80 crores of CAPEX has already been incurred: Rs. 50 crores capitalized and Rs. 30 crores in work-in-progress, mainly for radiology equipment. - Maharashtra MRI centers are in the final stages of implementation, with assets procured on deferred payments (only 20-25% paid initially). - Rajasthan expansion involves establishing around 10 labs by December and 25 labs plus 500 centers by Q4. - Deferred payment and lease models for equipment are being leveraged for capital efficiency. - The company is evaluating a mix of internal accruals and potential debt for funding CAPEX. - Additional CAPEX will support new PPP projects and retail network expansion, aiming for a substantial ramp-up in the coming years.

- The company is managing borrowings primarily for working capital and maintains tight control over debt. - For further expansion, including Rajasthan and other PPP projects, they are evaluating the most efficient use of capital, which may involve a combination of debt and equity. - No immediate plans or announcements have been made regarding new equity fundraising. - Updates on potential debt raising will be communicated once more clarity on Rajasthan projects emerges. - The company emphasizes minimizing borrowing to control financial impact and is open to both internal accruals and external funding options as appropriate.

- Maharashtra: 15 MRI centers are under implementation; 10 are near completion and awaiting inauguration. - Rajasthan: Establishing 10 labs soon; target of 25 labs and 500 centers by December, with remaining centers completed in Q4. - Pipeline: Several tenders are in various stages across different states; details kept confidential due to competitive nature. - No recent awarded tenders reported in past 5-6 months; attributed to tender timing and government processes, not reduced tender pipeline. - Ongoing discussions with different state authorities regarding upcoming tenders. - The company expects to announce results of some contracts in the near future.